Howden
published a 2026 report on how insurance can support the UK pharmaceutical and life-sciences sector through its current transition, reflecting an active dedicated life-sciences broking practice.
- Country
- United Kingdom
EU
Coverage
| EU | US | |
|---|---|---|
| insurance-risk | ✓ | ✓ |
Regulatorsfdaema
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Clinical-trial insurance brokerage | insurance-risk | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.